CLDN News Alert Celladon Corp (CLDN) 12.19 11/13/2014 17:29:

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:29 PM

Celladon Corp (CLDN) 12.19 $CLDN

Celladon Net loss of $8.35M
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:18AM CST

CLDN: 12.19 (+0.12)

Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Nov 12, 5:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
CLDN: 12.19 (+0.12)

Celladon Corporation to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Fri Nov 07, 3:05PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 12.19 (+0.12)

Celladon Corporation to Present at Credit Suisse Healthcare Investor Conference
GlobeNewswire - Wed Nov 05, 3:38PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 12.19 (+0.12)

Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R)
GlobeNewswire - Mon Nov 03, 5:00AM CST
-- Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR(R)
CLDN: 12.19 (+0.12)

Larsen MacColl Partners, LP Divests A&S Services Group, LLC
Business Wire - Fri Oct 31, 6:00AM CDT
Larsen MacColl Partners, LP ("LMP"

, announced today that on October 24, 2014 it sold its portfolio company, A&S Services Group, LLC and affiliates (collectively, "A&S"

, to Celadon Group, Inc. The purchase price was $55 million and LMP will realize a 24x multiple of its invested capital from the sale.
CLDN: 12.19 (+0.12)

Celadon Group Reports September Quarter Results and Declares Dividend
PR Newswire - Wed Oct 29, 4:20PM CDT
Celadon Group Inc. (NYSE : CGI) today reported its financial and operating results for the three months ended September 30, 2014, the first quarter of the Company's fiscal year ending June 30, 2015.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celadon Group Acquires A&S Services Group, LLC
PR Newswire - Mon Oct 27, 1:27PM CDT
Celadon Group, Inc. (NYSE: CGI) "Celadon", one of North America's premier transportation and logistics companies, today announced the acquisition of A&S Services Group, LLC ("A&S"

. A&S is a leading regional for-hire and dedicated truckload carrier based in New Freedom, PA. A&S's fleet operations provide dry van transportation services almost exclusively and principally serve the Mid-Atlantic and Northeast regions. A&S is also a major supplier of logistics, warehousing and distribution services in the area.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure
GlobeNewswire - Mon Oct 27, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a biotechnology industry leader in the field of cardiovascular gene therapy, today announced together with researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, the results of pre-clinical work on the membrane-bound form of the Stem Cell Factor (mSCF) gene therapy product candidate in the September 2014 online issue of Circulation Heart Failure. The paper is entitled "Stem Cell Factor Gene Therapy Improves Cardiac Function after Myocardial Infarction in Swine".
CLDN: 12.19 (+0.12)

Celadon Group Announces Executive Team Changes
PR Newswire - Tue Oct 21, 3:57PM CDT
Celadon Group, Inc. (NYSE: CGI) today announced changes to its executive team. The changes are effective immediately.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celadon Group Announces Dates for Earnings Release and Conference Call and for Upcoming Investor Conferences
PR Newswire - Fri Oct 03, 9:19AM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2015 first quarter results on Wednesday, October 29 after the close of the market. A conference call to discuss the first quarter results will be held Thursday, October 30 at 11:00 a.m. Eastern Time.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.51 (+0.17), DNDN: 0.13 (-0.03), VNDA: 12.17 (-0.65), OSIR: 13.30 (-0.20), CLDN: 12.19 (+0.12), GALE: 1.88 (-0.04), CTIC: 2.15 (-0.03), OTIC: 23.69 (+0.01)

Celladon to Present at the 2014 Stem Cell Meeting on the Mesa
GlobeNewswire - Wed Oct 01, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
CLDN: 12.19 (+0.12)

Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), CLDN: 12.19 (+0.12)

Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
PFE: 30.42 (unch), PTN: 0.75 (-0.02), CLDN: 12.19 (+0.12), AMGN: 160.85 (-1.08), NVS: 94.38 (+1.72)

Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LOXO: 11.51 (+0.17), ACET: 21.29 (-0.27), MAGS: 4.57 (+0.08), CLDN: 12.19 (+0.12)

Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CLDN: 12.19 (+0.12)

Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
CBPO: 66.35 (-2.38), CBM: 23.36 (-0.66), GILD: 104.20 (-2.70), CLDN: 12.19 (+0.12)

5 Stocks Moving on Unusual Volume
at The Street - Tue Aug 19, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
DRTX: 23.75 (-0.14), MVNR: 14.15 (-0.31), WBMD: 39.45 (-0.74), CRTO: 38.20 (+0.92), CLDN: 12.19 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...